text
"[""\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2023년 12월 31일\n)\n(단위 : 백만원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n씨씨알㈜\n비상장\n2005.01.02\n투자\n74\n13,489\n0.32\n-\n-\n-\n-\n13,489\n0.32\n-\n8,232\n320\n㈜퓨어스피어\n비상장\n2016.11.03\n투자\n300\n3,000\n6.52\n218\n-\n-\n-\n3,000\n6.52\n218\n13,925\n909\n프리미어 글로벌 이노베이션1호 투자조합\n비상장\n2017.06.15\n투자\n560\n-\n-\n2,317\n-\n-236\n-371\r\n-\n-\n2,081\n43,998\n5,864\n라이프코어-이앤 신기술 사업투자조합 1호\n비상장\n2017.08.10\n투자\n500\n-\n-\n500\n-\n-\n-\n-\n-\n500\n3,802\n-65\n㈜클리노믹스\n상장\n2018.07.20\n투자\n1,000\n138,928\n1.04\n920\n69,464\n-\n-385\n208,392\n0.64\n535\n97,104\n-10,234\n㈜티움바이오\n상장\n2019.04.30\n투자\n3,000\n125,000\n0.53\n1,575\n-\n-\n-354\n125,000\n0.45\n1,221\n96,259\n-31,402\n시너지 바이오 헬스케어 벤처펀드\n비상장\n2019.05.16\n투자\n601\n-\n-\n1,768\n-\n-\n663\n-\n-\n2,431\n24,694\n-504\n보고신기술사업금융전문투자형 사모투자신탁 제2호\n비상장\n2019.06.04\n투자\n1,000\n-\n-\n206\n-\n-206\n-\n-\n-\n-\n2,904\n-11,196\nDS Benefit,XV 전문투자형 사모투자신탁\n비상장\n2020.05.29\n투자\n300\n-\n-\n300\n-\n-\n-18\n-\n-\n282\n4,443\n2\n수성코스닥벤처 M6 전문투자형 사모투자신탁\n비상장\n2020.10.16\n투자\n2,000\n-\n-\n2,282\n-\n-2,282\n-\n-\n-\n-\n31,141\n513\n프리미어 글로벌 이노베이션 2호 투자조합\n비상장\n2020.11.03\n투자\n250\n-\n-\n3,472\n-\n664\n321\n-\n-\n4,457\n62,339\n-1,947\n㈜엘베이스\n비상장\n2020.12.28\n투자\n3,000\n93,053\n5.97\n2,000\n60,864\n1,000\n-\n153,917\n8.16\n3,000\n2,427\n3,007\n신보2021제14차유동화전문회사 제1-3회 무보증후순위공모사채\n비상장\n2021.08.27\n투자\n270\n-\n-\n270\n-\n-\n-\n-\n-\n270\n-\n-\nNH 앱솔루트 코스닥벤처 메자닌 1호\n비상장\n2021.09.23\n투자\n2,000\n-\n-\n1,865\n-\n-\n222\n-\n-\n2,087\n58,230\n-2,218\n더블유피 기술혁신 스타트업 2호조합\n비상장\n2021.11.19\n투자\n200\n-\n-\n350\n-\n150\n-\n-\n-\n500\n1,296\n-39\n디지털 이노베이션 벤처투자조합\n비상장\n2021.12.16\n투자\n3,000\n-\n-\n3,000\n-\n-\n-\n-\n-\n3,000\n10,040\n-214\nList Biotherapeutics, Inc.\n비상장\n2022.01.14\n투자\n3,570\n10,000\n3.48\n3,570\n-\n-\n-\n10,000\n3.48\n3,570\n60,224\n-2,694\n수성프로젝트 T1 일반 사모투자신탁\n비상장\n2022.01.26\n투자\n2,000\n-\n-\n2,000\n-\n-\n-44\n-\n-\n1,956\n15,867\n-171\n㈜글라세움 우선주\n비상장\n2022.04.01\n투자\n3,000\n187,500\n1.69\n3,011\n-\n-\n-34\n187,500\n1.69\n2,977\n20,480\n-6,453\n㈜넥스트바이오메디컬\n비상장\n2023.01.11\n투자\n1,980\n-\n-\n-\n60,000\n1,980\n-\n60,000\n0.86\n1,980\n32,255\n-5,587\n마스트파트너스 사모투자신탁 1호\n비상장\n2023.05.26\n투자\n7,000\n-\n-\n-\n-\n7,000\n-\n-\n-\n7,000\n-\n-\nNeuroBo Pharmaceuticals, Inc.\n상장\n2023.06.21\n투자\n33\n-\n-\n-\n6,397\n33\n-3\n6,397\n0.13\n30\n42,498\n-1,751\n\xa0프리미어 IBK K-바이오 백신 투자조합\xa0\n비상장\n2023.12.15\n투자\n300\n-\n-\n-\n-\n300\n-\n-\n-\n300\n-\n-\n한국제약협동조합\n비상장\n1978.04.04\n공동출자\n162\n663\n6.26\n162\n150\n15\n-\n813\n6.86\n177\n12,090\n5\n대원메디테크㈜\n비상장\n2011.04.12\n경영참여\n2,300\n2,799,999\n64.42\n-\n-\n-\n-\n2,799,999\n64.42\n-\n156\n-2,534\n㈜다나젠\n비상장\n2015.12.11\n경영참여\n40\n655,184\n27.58\n1,003\n-\n-\n-\n655,184\n27.58\n1,003\n18,969\n3,348\nDAEWON PHARMACEUTICAL (Vietnam) Co., Ltd.\n비상장\n2017.07.31\n경영참여\n430\n-\n100.00\n836\n-\n276\n-\n-\n100.00\n1,112\n649\n-116\n대원헬스케어㈜\n비상장\n2021.05.26\n경영참여\n14,114\n60,553\n83.53\n12,394\n514,175\n5,089\n-6,054\n574,728\n86.88\n11,429\n31,963\n-2,238\n㈜에스디생명공학\n상장\n2023.12.21\n경영참여\n40,000\n-\n-\n-\n80\n40,000\n-\n80\n72.90\n40,000\n67,877\n-68,083\n합 계\n4,087,369\n-\n44,019\n-\n53,783\n-6,057\n4,798,499\n-\n91,745\n-\n-\n주1) 상기표 '최근사업연도 재무현황'은 2022년도(말)\xa0개별/별도\xa0기준입니다.\xa0\r\n주2) '마스트파트너스 일반사모투자신탁 제1호' 및\xa0'프리미어 IBK K-바이오 백신 투자조합'의 경우 2023년도\xa0결성되어\xa0최근 사업연도 재무현황 기재를 생략하였습니다.\xa0\r\n""]"
